Günther U, Hoefer-Janker H, Scheef W
Dev Biol Stand. 1977;38:507-8.
6 patients with solid tumours (4 malignant melanomas, one fibrosarcoma, one osteogenic sarcoma) received i.v. C. parvum alone or in combination therapy (radiotherapy, Levamisole and/or vitamin A). The single doses of C. parvum ranged from 5.0-7.5 mg/m2; No. of doses ranged from 1-8; interval between doses ranged from 2-140 days. 2 patients with malignant melanoma had no measurable disease, one of them (stage I) still has no evidence of disease. The patient with fibrosarcoma appeared to have a minor decrease in size of some of the lung metastases for a short time (ca 4 weeks), but soon progressed as well as the other 4 patients. Except for the one patients still having no evidence of disease the other 5 are dead of disease. Survival time did not appear to correlate either with systemic reaction to C. parvum or with No. of doses of C. parvum. The one minor response was observed in a patient receiving a total of 8 doses; but response was seen already after 3 doses, and progression occurred after 6 doses. So this change of lung metastases might have been unrelated to this therapy. Summarizing, there was no evident anti-tumour effect observed after i.v. C. parvum in these patients with solid tumours.
6例实体瘤患者（4例恶性黑色素瘤、1例纤维肉瘤、1例骨肉瘤）接受了静脉注射微小隐孢子虫单独治疗或联合治疗（放疗、左旋咪唑和/或维生素A）。微小隐孢子虫的单次剂量为5.0 - 7.5mg/m²；给药次数为1 - 8次；给药间隔为2 - 140天。2例恶性黑色素瘤患者无可测量病灶，其中1例（I期）仍无疾病证据。纤维肉瘤患者的部分肺转移灶大小在短时间内（约4周）似乎略有缩小，但很快病情进展，其他4例患者也是如此。除1例仍无疾病证据的患者外，其他5例均死于疾病。生存时间似乎与对微小隐孢子虫的全身反应或微小隐孢子虫的给药次数均无关联。在1例总共接受8次给药的患者中观察到轻微反应；但在3次给药后即出现反应，6次给药后病情进展。因此，肺转移灶的这种变化可能与该治疗无关。总之，在这些实体瘤患者中静脉注射微小隐孢子虫后未观察到明显的抗肿瘤效果。
